KDM5A was recently reported to be required for cMYC-driven transcription in MM cells, and a KDM5-selective inhibitor in this same study limited growth of MM cell lines and patient samples, reduced tumor burden and improved survival in a disseminated tumor model, and inhibited tumor growth in a subcutaneous plasmacytoma model (108). This evidence concerns the gene MYC and Miyoshi myopathy.